Loss of O6‐Methylguanine‐DNA Methyltransferase Protein Expression by Immunohistochemistry Is Associated With Response to Capecitabine and Temozolomide in Neuroendocrine Neoplasms
World Journal of Surgery · 2025
DOI: 10.1002/wjs.12471 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Surgery, 2025. Verfasst von Mark G Evans und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pathology and Clinical and Translational Research, Caris Life Sciences, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Tumor Suppressor Proteins, DNA Repair Enzymes, DNA Modification Methylases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
A recent prospective phase II study (ECOG‐ACRIN E2211) demonstrated that MGMT deficiency was associated with a significant response to capecitabine and temozolomide (CAPTEM) in pancreatic neuroendocrine neoplasms (NENs); however, routine MGMT analysis in NENs was not recommended. Our study sought to demonstrate whether loss of MGMT protein expression is associated with improved overall survival (OS) in patients receiving CAPTEM for NENs from various tumor sites. Materials and Methods Paraffin‐embedded tumor samples were evaluated by immunohistochemistry (IHC) using an MGMT monoclonal antibody. Intact MGMT protein expression (i.e., IHC positivity) was defined as any staining intensity (> 1+) in ≥ 36% of neoplastic cells according to an internal validation study. IHC and pyrosequencing for MGMT promotor methylation was performed in an independent cohort of 58 NENs. Real‐world OS was extrapolated from insurance claims data with Kaplan–Meier estimates from the date of first CAPTEM administration to the last date of contact.
Results
The study cohort included 80 patients (42 men and 38 women) with a median age of 57 years (range: 19–89). They had various NENs (33 pancreatic, 17 intestinal, 7 pulmonary, 8 other, and 15 of unknown origin) treated with CAPTEM. The median OS for the 48 patients with MGMT negative tumors was 31 months compared to 17.5 months for the 32 patients whose tumors were MGMT positive by IHC (HR: 1.75 [95% CI: 1.066–2.87] and p = 0.025). IHC results from the independent cohort of 58 NENs showed only 57% concordance with pyrosequencing results.
Conclusions
MGMT promotor status by IHC may be a clinically useful indicator that predicts improved OS for NENs treated with CAPTEM, but IHC does not reliably correlate with the findings of MGMT promoter methylation by pyrosequencing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Pathology and Clinical and Translational Research, Caris Life Sciences, Phoenix, Arizona, USA.
- Precision Medicine Program, Hoag Family Cancer Institute, Newport Beach, California, USA.
- Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
- Basis Phoenix High School, Phoenix, Arizona, USA.
- Translational Genomics Research Institute, Phoenix, Arizona, USA.
ORCID-Profile: Michael J Demeure
Zitieren
APA
Evans, M. G., Xiu, J., Darabi, S., Crymes, A., Bedeir, A., Bryant, D. A., Oberley, M. J., & Demeure, M. J. (2025). Loss of O6‐Methylguanine‐DNA Methyltransferase Protein Expression by Immunohistochemistry Is Associated With Response to Capecitabine and Temozolomide in Neuroendocrine Neoplasms. World Journal of Surgery. https://doi.org/10.1002/wjs.12471
Vancouver
Evans MG, Xiu J, Darabi S, Crymes A, Bedeir A, Bryant DA, et al. Loss of O6‐Methylguanine‐DNA Methyltransferase Protein Expression by Immunohistochemistry Is Associated With Response to Capecitabine and Temozolomide in Neuroendocrine Neoplasms. World Journal of Surgery. 2025. doi:10.1002/wjs.12471
BibTeX
@article{Evans2025,
author = {Evans, Mark G and Xiu, Joanne and Darabi, Sourat and Crymes, Anthony and Bedeir, Adam and Bryant, David A and Oberley, Matthew J and Demeure, Michael J},
title = {Loss of O6‐Methylguanine‐DNA Methyltransferase Protein Expression by Immunohistochemistry Is Associated With Response to Capecitabine and Temozolomide in Neuroendocrine Neoplasms},
journal = {World Journal of Surgery},
year = {2025},
doi = {10.1002/wjs.12471}
}
EUVIMED